Stocktoria
Liquidia Corp LQDA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-07-26
Liquidia Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $158.3M | $14.0M | $17.5M | $15.9M | $12.9M |
| R&D expense | $39.3M | $47.8M | $43.2M | $19.4M | $20.5M |
| SG&A expense | $157.2M | $81.6M | $44.7M | — | — |
| Operating income | -$51.4M | -$121.3M | -$73.4M | -$38.8M | -$33.8M |
| Interest expense | — | — | $6.3M | $2.3M | $762,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$68.9M | -$128.3M | -$78.5M | -$41.0M | -$34.6M |
| EPS (diluted) | $-0.80 | $-1.63 | $-1.21 | $-0.67 | $-0.70 |
| Operating cash flow | -$35.7M | -$93.4M | -$41.6M | -$28.6M | -$34.0M |
| Free cash flow | -$40.0M | -$98.4M | -$42.9M | -$29.2M | -$34.1M |
| Cash & equivalents | $190.7M | $176.5M | $83.7M | $93.3M | $57.5M |
| Inventory | $23.8M | $241,000 | — | — | — |
| Total assets | $327.9M | $230.3M | $118.3M | $129.2M | $93.7M |
| Total liabilities | $283.2M | $150.9M | $71.0M | $38.8M | $28.5M |
| Shareholders' equity | $44.7M | $79.4M | $47.3M | $90.4M | $65.3M |
Source: SEC EDGAR filings · CIK 0001819576 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.